In RCC, immunosuppression induced by the expression of PDL1, PDL2, and B7-1 or B7-2 is inhibited by nivolumab (anti-PD1) or ipilimumab (anti-CTLA4) (treatment referred to as “immune checkpoint inhibitor therapy”). Here, CD80 is linked to renal cell carcinoma.